Erschienen in:
17.12.2021 | Editorial
Quantifying is believing: Techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications
verfasst von:
Robert J. H. Miller, MD, Nowell Fine, MD, SM
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 6/2022
Einloggen, um Zugang zu erhalten
Excerpt
The clinical use of bone radiotracer imaging for the diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is growing exponentially.
1,2 The combination of highly accurate non-invasive testing and targeted therapies which demonstrate clinical benefit,
3,4 has created a perfect storm for increasing use and ongoing advancement of the technique. As a result, patients with less advanced disease are being referred for imaging including patients with identified genetic mutations during cascade screening without evidence of heart failure.
5,6 With changing referral patterns, there has been increasing focus on the need to confirm diffuse myocardial radiotracer uptake on single photon emission computed tomography (SPECT) imaging to ensure accurate diagnosis.
2,7 With the growing importance of SPECT, there have also been several efforts at quantifying radiotracer uptake from the images. …
